32.63
price down icon2.16%   -0.72
after-market Handel nachbörslich: 32.63
loading

Genmab Adr Aktie (GMAB) Neueste Nachrichten

pulisher
08:01 AM

Federated Hermes Inc. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat

08:01 AM
pulisher
Jan 31, 2026

What is HC Wainwright’s Estimate for Genmab A/S Q4 Earnings? - Defense World

Jan 31, 2026
pulisher
Jan 30, 2026

What is HC Wainwright's Estimate for Genmab A/S Q4 Earnings? - MarketBeat

Jan 30, 2026
pulisher
Jan 29, 2026

GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment - Chartmill

Jan 29, 2026
pulisher
Jan 28, 2026

Genmab A/S (NASDAQ:GMAB) Shares Gap DownHere's What Happened - MarketBeat

Jan 28, 2026
pulisher
Jan 26, 2026

GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation - Chartmill

Jan 26, 2026
pulisher
Jan 24, 2026

GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals - Chartmill

Jan 24, 2026
pulisher
Jan 24, 2026

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Jan 24, 2026
pulisher
Jan 24, 2026

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Jan 24, 2026
pulisher
Jan 20, 2026

Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside - Finviz

Jan 20, 2026
pulisher
Jan 16, 2026

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - GlobeNewswire Inc.

Jan 16, 2026
pulisher
Jan 16, 2026

Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN

Jan 16, 2026
pulisher
Jan 15, 2026

Genmab A/S (GMAB): A Bull Case Theory - Finviz

Jan 15, 2026
pulisher
Jan 15, 2026

Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 - Investor's Business Daily

Jan 15, 2026
pulisher
Jan 15, 2026

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Jan 15, 2026
pulisher
Jan 15, 2026

Eagle Global Advisors LLC Buys 34,175 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat

Jan 15, 2026
pulisher
Jan 15, 2026

Genmab ADR Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Jan 15, 2026
pulisher
Jan 14, 2026

Genmab A/S (NASDAQ:GMAB) Hits New 52-Week HighTime to Buy? - MarketBeat

Jan 14, 2026
pulisher
Jan 14, 2026

Genmab A/S (OTCMKTS:GNMSF) Reaches New 1-Year HighShould You Buy? - MarketBeat

Jan 14, 2026
pulisher
Jan 13, 2026

Moderna Stock Gets Healthy Relative Strength Rating Jump - Investor's Business Daily

Jan 13, 2026
pulisher
Jan 13, 2026

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN

Jan 13, 2026
pulisher
Jan 11, 2026

Quoin Pharm ADR clears technical benchmark, hitting 90-plus RS rating - MSN

Jan 11, 2026
pulisher
Jan 08, 2026

Genmab A/SAmerican Depositary Shares (NQ: GMAB - FinancialContent

Jan 08, 2026
pulisher
Jan 07, 2026

Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week HighHere's What Happened - MarketBeat

Jan 07, 2026
pulisher
Jan 07, 2026

Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN

Jan 07, 2026
pulisher
Jan 02, 2026

Genmab A/S (NASDAQ:GMAB) Shares Down 3.5% – Here’s Why - Defense World

Jan 02, 2026
pulisher
Dec 31, 2025

Genmab A/S (NASDAQ:GMAB) Stock Price Down 3.5%Time to Sell? - MarketBeat

Dec 31, 2025
pulisher
Dec 31, 2025

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus - TechStock²

Dec 31, 2025
pulisher
Dec 30, 2025

Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN

Dec 30, 2025
pulisher
Dec 30, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 30, 2025
pulisher
Dec 30, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Dec 30, 2025
pulisher
Dec 29, 2025

Genmab Portfolio Prioritization Update - GlobeNewswire

Dec 29, 2025
pulisher
Dec 28, 2025

Genmab–BioNTech cancer antibody trial ends early: What investors need to know - MSN

Dec 28, 2025
pulisher
Dec 26, 2025

Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know - TipRanks

Dec 26, 2025
pulisher
Dec 26, 2025

This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131% - Investor's Business Daily

Dec 26, 2025
pulisher
Dec 23, 2025

Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year HighStill a Buy? - MarketBeat

Dec 23, 2025
pulisher
Dec 19, 2025

Squarepoint Ops LLC Has $1.95 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Dec 19, 2025
pulisher
Dec 16, 2025

China Universal Asset Management Co. Ltd. Has $381,000 Stake in Genmab A/S Sponsored ADR $GMAB - Defense World

Dec 16, 2025
pulisher
Dec 16, 2025

The 5 Best Stocks To Buy And Watch Right Now - Investor's Business Daily

Dec 16, 2025
pulisher
Dec 11, 2025

Pipeline of Proprietary Antibodies - flow – Deutsche Bank

Dec 11, 2025
pulisher
Dec 11, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 86,842 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat

Dec 11, 2025
pulisher
Dec 10, 2025

Genmab A/S Sponsored ADR $GMAB Shares Bought by First Trust Advisors LP - Defense World

Dec 10, 2025
pulisher
Dec 09, 2025

Quoin Pharm ADR Joins Rank Of Stocks With RS Ratings Over 90 - MSN

Dec 09, 2025
pulisher
Dec 09, 2025

Dow Jones Stock Caterpillar In Buy Zone After Recent Breakout Move - Investor's Business Daily

Dec 09, 2025
pulisher
Dec 08, 2025

Marshall Wace LLP Cuts Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Dec 08, 2025
pulisher
Dec 07, 2025

Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - Defense World

Dec 07, 2025
pulisher
Dec 06, 2025

AI Plays Lead Five Stocks To Watch Near Buy Points - Investor's Business Daily

Dec 06, 2025
pulisher
Dec 05, 2025

Arrowstreet Capital Limited Partnership Raises Position in Genmab A/S Sponsored ADR $GMAB - Defense World

Dec 05, 2025
pulisher
Dec 05, 2025

JPMorgan Chase & Co. Grows Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Dec 05, 2025
$100.07
price down icon 1.00%
$96.95
price down icon 1.27%
$113.75
price down icon 2.59%
$156.87
price down icon 0.60%
biotechnology ONC
$340.38
price down icon 2.75%
Kapitalisierung:     |  Volumen (24h):